RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals

April 16, 2026 - 02:18

The U.S. Food and Drug Administration is moving to re-evaluate its stance on a group of unapproved chemicals known as peptides, following a surge in public interest and promotion by high-profile figures. The agency has convened a panel of independent scientific advisers to scrutinize the safety of seven specific peptides.

This review, scheduled for a key meeting in July, will focus on a critical regulatory question: whether these substances can be compounded, or custom-made, by pharmacies on a larger scale without compromising patient safety. Currently, these peptides are not FDA-approved for any specific medical use, meaning they have not undergone the agency's rigorous review process for safety and effectiveness.

The compounds in question are often marketed for a wide range of unverified benefits, from anti-aging and weight loss to enhanced athletic performance. Their popularity has grown despite a lack of robust clinical evidence, leading to concerns about potential health risks from impurities, incorrect dosing, or unknown side effects.

The upcoming advisory committee meeting represents a significant regulatory step. The external experts will examine available data to advise the FDA on the risks associated with pharmacy-level production. Their recommendations could lead to new guidelines that either relax current restrictions or reinforce the need for strict controls, directly impacting the availability of these controversial substances.